Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function

Background. Direct-acing antiviral agents are highly efficient treatment options for chronic hepatitis C virus (HCV) infection after renal allograft transplantation. Treatment options for patients with impaired graft function remain limited. Therefore, we assessed the effectiveness and safety of gra...

Full description

Bibliographic Details
Main Authors: Ute Eisenberger, MD, Justa Friebus-Kardash, MD, Hana Guberina, MD, Andreas Kribben, MD, Oliver Witzke, MD, Katharina Willuweit, MD, Guido Gerken, MD, Kerstin Herzer, MD
Format: Article
Language:English
Published: Wolters Kluwer 2019-01-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000860

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000860

Similar Items